1. Pink Sheet
  2. >>Market Access

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says

 
• By Cathy Kelly

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

PBMs And Patents Are Two Important Drug Pricing Issues For Linda Khan and the FTC.

The Federal Trade Commission is planning to announce preliminary results from its ongoing in-depth investigation of potentially anti-competitive behavior in the pharmacy benefit manager industry much sooner than previous efforts, according to commission Chair Lina Khan.

“It’s very much traditional for these ‘6b’ studies at the agency to take five years, six years” but “we’ve been pushing to make that move more quickly … and in the coming one to three months, we’ll be able to share more on that,” Khan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.